Rutgers Study Links Popular GLP-1 Diabetes and Weight Loss Drugs to Rare Vision Loss Risk

New Safety Signal Emerges for Ozempic and Wegovy

Researchers at Rutgers University have identified a potential vision risk associated with glucagon-like peptide-1 receptor agonists, a class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The large study, published in Annals of Internal Medicine, analyzed data from U.S. adults ages 18 to 65 with Type 2 diabetes and found that GLP-1 use correlated with a modest increase in the likelihood of developing ischemic optic neuropathy, a rare eye condition that can cause sudden and potentially permanent vision loss.

Ischemic optic neuropathy occurs when blood flow to the optic nerve diminishes, disrupting the transmission of visual information from the eye to the brain. The condition typically manifests in the non-arteritic anterior form, affecting approximately 80 percent of cases. Rather than causing complete blindness, it usually impacts part of the vision in one eye, with patients potentially experiencing sudden blurriness, dimming, or missing patches in their visual field. The resulting vision loss is frequently permanent, though about one-third of affected patients experience some recovery within the first six months after onset.

The Size of the Risk

While the absolute risk remains small, the numbers are concrete enough to warrant attention. Chintan Dave, lead researcher and associate professor at the Ernest Mario School of Pharmacy at Rutgers, quantified the finding as approximately three to four additional cases per 10,000 patients treated with GLP-1 medications over an 18-month period. This modest increase matters precisely because ischemic optic neuropathy, though uncommon, can result in sudden vision loss that may be irreversible.

The study identified demographic patterns among patients who developed the eye condition. Cases occurred more frequently among men and older adults, particularly those between ages 50 and 65. This demographic breakdown suggests that certain populations may face elevated baseline risk and therefore warrant closer monitoring.

Causation Remains Uncertain

Crucially, the researchers emphasize that their findings establish an association rather than direct causation. GLP-1 medications have not been proven to directly damage the optic nerve. Other underlying health conditions or patient-specific factors could potentially explain the observed increased risk. Dave and colleagues stress that additional research is necessary to determine whether the medications themselves contribute to ischemic optic neuropathy or whether other variables account for the correlation.

Despite this uncertainty, the timing of the finding carries weight. GLP-1 drugs were originally developed to manage blood sugar in Type 2 diabetes patients, but they have become increasingly prescribed for weight loss purposes among individuals both with and without diabetes. Their widening use amplifies the importance of continued safety surveillance and patient awareness.

Clinical Implications and Next Steps

The research team recommends that clinicians and patients remain aware of this potential association, particularly given the irreversible nature of ischemic optic neuropathy when it occurs. Early recognition of sudden vision changes and prompt evaluation by an ophthalmologist may be especially critical for patients at higher baseline risk—notably older men taking these medications.

Beyond this specific finding, GLP-1 medications have demonstrated genuine benefits in reducing risks of certain cardiovascular and kidney problems while controlling blood sugar and managing weight. Scientists continue investigating potential side effects as these drugs become more widespread and their long-term safety profile becomes clearer. The Rutgers study, conducted by researchers including Kamika Reynolds, Kimberly O'Malley, and Jason Roy, contributes an important data point to this evolving body of safety literature.